MX2023003556A - Composiciones farmaceuticas. - Google Patents
Composiciones farmaceuticas.Info
- Publication number
- MX2023003556A MX2023003556A MX2023003556A MX2023003556A MX2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A MX 2023003556 A MX2023003556 A MX 2023003556A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- active pharmaceutical
- pharmaceutical ingredient
- nilotinib
- adsorbent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 abstract 1
- 239000003463 adsorbent Substances 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001346 nilotinib Drugs 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan composiciones farmacéuticas que incluyen una mezcla de un ingrediente farmacéutico activo lipofílico tal como nilotinib, un polímero hidrofílico, uno o más de tensoactivos, y de manera opcional un adsorbente. También se describen métodos para la preparación y el uso de tales composiciones farmacéuticas. En un aspecto, se describe en la presente una dispersión sólida amorfa que comprende el ingrediente farmacéutico activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020118608 | 2020-09-29 | ||
PCT/CN2021/121695 WO2022068876A1 (en) | 2020-09-29 | 2021-09-29 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003556A true MX2023003556A (es) | 2023-06-13 |
Family
ID=80951208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003556A MX2023003556A (es) | 2020-09-29 | 2021-09-29 | Composiciones farmaceuticas. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20230414613A1 (es) |
EP (1) | EP4221690A1 (es) |
JP (1) | JP2023543815A (es) |
KR (1) | KR20230097021A (es) |
CN (1) | CN116635015A (es) |
AU (1) | AU2021353684A1 (es) |
CA (1) | CA3193829A1 (es) |
MX (1) | MX2023003556A (es) |
WO (1) | WO2022068876A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114869853A (zh) * | 2022-05-25 | 2022-08-09 | 济宁医学院 | 一种柚皮素固体分散体及其制备方法 |
WO2023235267A2 (en) * | 2022-05-28 | 2023-12-07 | Avalyn Pharma Inc. | Nintedanib and nintedanib combination dry powder compositions and uses |
WO2024142002A1 (en) * | 2022-12-29 | 2024-07-04 | Renata Pharmaceuticals (Ireland) Limited | Pharmaceutical suspension of nilotinib |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
CN106932522A (zh) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | 一种尼罗替尼中杂质化合物i含量的测定方法 |
US10874671B2 (en) * | 2019-02-18 | 2020-12-29 | Slayback Pharma Llc | Pharmaceutical compositions of nilotinib |
-
2021
- 2021-09-29 MX MX2023003556A patent/MX2023003556A/es unknown
- 2021-09-29 JP JP2023519417A patent/JP2023543815A/ja active Pending
- 2021-09-29 WO PCT/CN2021/121695 patent/WO2022068876A1/en active Application Filing
- 2021-09-29 CN CN202180076129.9A patent/CN116635015A/zh active Pending
- 2021-09-29 EP EP21874531.3A patent/EP4221690A1/en active Pending
- 2021-09-29 AU AU2021353684A patent/AU2021353684A1/en active Pending
- 2021-09-29 CA CA3193829A patent/CA3193829A1/en active Pending
- 2021-09-29 KR KR1020237014087A patent/KR20230097021A/ko unknown
-
2023
- 2023-03-28 US US18/191,637 patent/US20230414613A1/en active Pending
-
2024
- 2024-03-19 US US18/609,790 patent/US20240226102A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3193829A1 (en) | 2022-04-07 |
US20230414613A1 (en) | 2023-12-28 |
US20240226102A1 (en) | 2024-07-11 |
EP4221690A1 (en) | 2023-08-09 |
JP2023543815A (ja) | 2023-10-18 |
KR20230097021A (ko) | 2023-06-30 |
CN116635015A (zh) | 2023-08-22 |
WO2022068876A1 (en) | 2022-04-07 |
AU2021353684A1 (en) | 2023-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023003556A (es) | Composiciones farmaceuticas. | |
AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
PH12021550701A1 (en) | Ionizable amine lipids | |
PH12021551279A1 (en) | Modified amine lipids | |
PL2029121T3 (pl) | Transdermalny system terapeutyczny zawierający cząstki substancji czynnej, o zwiększonym przepływie substancji czynnej | |
NO20074100L (no) | Mikroimplantater for okulaer administrering | |
MX2023003689A (es) | Composiciones farmaceuticas de dispersiones de solidos amorfos y metodos de preparacion de las mismas. | |
WO2007022255A3 (en) | Pharmaceutical formulations for sustained release | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
WO2002074247A8 (en) | Pharmaceutical formulations for sustained release | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2004066910A3 (en) | Controlled release modifying complex and pharmaceutical compositions thereof | |
MX2010004222A (es) | Formulaciones solidas de compuestos cristalinos. | |
SI2046292T1 (sl) | Formulacije za benzimidazolil piridil etre | |
WO2011067791A3 (en) | Process for preparing pharmaceutical ophthalmic compositions | |
WO2005044221A3 (de) | Feste wirkstoff-formulierung | |
WO2010021607A3 (en) | Pharmaceutical formulation | |
WO2012167321A8 (en) | Composition and method for enhancing the physical stability of agricultural oil-based suspension formulations | |
WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
MX2022007707A (es) | Comprimidos de edoxaban. | |
WO2006102533A3 (en) | Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates | |
MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
EP4166155A4 (en) | COMPOSITION COMPRISING A PENTAPEPTIDE AS ACTIVE PRINCIPLE | |
MX2017005163A (es) | Composiciones de liberación prolongada de onapristona y métodos. |